Kura Oncology (KURA) has shared an announcement.
Kura Oncology, Inc.’s Board of Directors, following the Compensation Committee’s recommendation, has amended its Equity Incentive Plan to increase the authorized shares for issuance by 5.5 million, a move that received stockholder approval on June 5, 2024. Additionally, during the Annual Meeting, stockholders elected two Class I directors, ratified the appointment of Ernst & Young LLP as their independent auditor for the upcoming fiscal year, approved executive compensation, and greenlit the amended incentive plan. This strategic step is a significant development for investors tracking company growth and governance.
See more data about KURA stock on TipRanks’ Stock Analysis page.
